Letter: should anti-viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma? Authors' reply
Aliment Pharmacol Ther
.
2017 Jan;45(1):182-183.
doi: 10.1111/apt.13849.
Authors
D Lin
1
,
H-I Yang
2
,
J Hoang
3
,
M H Nguyen
3
Affiliations
1
Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
2
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
3
Division of GI and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
PMID:
27910153
DOI:
10.1111/apt.13849
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents
Carcinoma, Hepatocellular / virology*
Hepatitis B
Hepatitis B virus*
Hepatitis B, Chronic
Humans
Liver Neoplasms / virology
Substances
Antiviral Agents